Immunotoxicity from checkpoint inhibitor therapy: clinical features and underlying mechanisms.
Immunology
; 159(2): 167-177, 2020 02.
Article
in En
| MEDLINE
| ID: mdl-31646612
ABSTRACT
Immune checkpoint inhibition with monoclonal antibodies is becoming increasingly commonplace in cancer medicine, having contributed to a widening of therapeutic options across oncological indications. Disruption of immune tolerance is the key mechanism of action of checkpoint inhibitors and although immune-related adverse events are a typical class effect of these compounds, the relationship between toxicity and response is not fully understood. Awareness and vigilance are paramount in recognizing potentially life-threatening toxicities and managing them in a timely manner. In this review article, we provide an overview of the clinical features, pathological findings and management principles of common immune-related toxicities, attempting to provide mechanistic insight into an increasingly common complication of cancer therapy.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Endocrine System Diseases
/
Chemical and Drug Induced Liver Injury
/
Molecular Targeted Therapy
/
Antineoplastic Agents, Immunological
/
Gastrointestinal Diseases
/
Immune Tolerance
/
Immunotherapy
/
Lung Diseases
/
Neoplasms
Type of study:
Etiology_studies
/
Risk_factors_studies
Limits:
Animals
/
Humans
Language:
En
Journal:
Immunology
Year:
2020
Type:
Article
Affiliation country:
United kingdom